Be part of the knowledge.™

Transformation of Treatment Strategies for ATTR Amyloidosis

Media Formats

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details

Overview
The treatment landscape for ATTR amyloidosis is changing. And clinicians can potentially look forward to having more treatment options for their patients through ongoing studies that use strategies for reducing the production of transthyretin (TTR) protein. To hear more, join Dr. Marianna Fontana, Director of the UCL CMR unit at the Royal Free Hospital. She is Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, UK.

Recommended

Details

Overview
The treatment landscape for ATTR amyloidosis is changing. And clinicians can potentially look forward to having more treatment options for their patients through ongoing studies that use strategies for reducing the production of transthyretin (TTR) protein. To hear more, join Dr. Marianna Fontana, Director of the UCL CMR unit at the Royal Free Hospital. She is Professor of Cardiology and Honorary Consultant Cardiologist at the National Amyloidosis Centre, Division of Medicine, University College London, UK.